Biotest AG · ISIN: DE0005227235 · EQS - Company News

Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million

PRESS RELEASE Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million   Product sales and toll manufacturing increased by 13,7% to € 414 million, in part thanks to the growth of Yimmugo® Adjusted EBIT was maintained at previous year's level as growing core business gradually replaces earnings  from technology transfer and development services Biotest submitted initial marketing authorization application for its Fibrinogen Concentrate (BT524) following the decentralized...

XETR:BIO3 Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Biotest AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (1)
Short Selling (UK) (0)
14 November 2024 10:14AM
Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million
DE0005227235
PRESS RELEASE Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million   Product sales and toll manufacturing increased by 13,7% to € 414 million, in part thanks to the growth of Yimmugo® Adjusted EBIT was maintained at previous year's level as growing core business gradually replaces earnings  from technology transfer and ...
Biotest AG
About the publication
14 November 2024 08:56AM
Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged
DE0005227235
Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)   Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged   Dreieich, Germany, November 14, 2024. The Board of Management currently expects a revenue increase in the low single-digit percentage range for the 2024 financial year compare...
Biotest AG
About the publication
29 October 2024 09:00AM
Biotest and SteinCares partner to improve access to plasma-derived products in Latin America
DE0005227235
PRESS RELEASE   Biotest and SteinCares partner to improve access to plasma-derived products in Latin America   Financial and strategic reliability is key driver of partnership to start to penetrate Latin American markets with plasma-derived Factor VIII products Agreement will be the first step to its expand our commercial footprint in the are...
Biotest AG
About the publication
02 October 2024 02:00PM
Strategic agreement signed for distribution of Yimmugo® in the United States based on the framework established in July
DE0005227235
  PRESS RELEASE     Strategic agreement signed for distribution of Yimmugo® in the United States based on the framework established in July   All contractual terms finalized and definitive agreement with Kedrion signed Expected to generate revenues of more than $1 billion for Biotest during the 7-year term Preparations for U.S. launch of ...
Biotest AG
About the publication
12 September 2024 03:00PM
Change in the Chief Financial Officer at Biotest AG
DE0005227235
PRESS RELEASE    Change in the Chief Financial Officer at Biotest AG   Martin Möller to assume role of Chief Financial Officer (CFO) on the Management Board for 6 months starting September 14 Dreieich, Germany, September 12, 2024. The Supervisory Board of Biotest AG announced today that the former Chief Financial Officer, Ms. Ainhoa Mendizabal...
Biotest AG
About the publication
12 September 2024 03:00PM
Change in the Chief Financial Officer at Biotest AG
DE0005227235
PRESS RELEASE    Change in the Chief Financial Officer at Biotest AG   Martin Möller to assume role of Chief Financial Officer (CFO) on the Management Board for 6 months starting September 14 Dreieich, Germany, September 12, 2024. The Supervisory Board of Biotest AG announced today that the former Chief Financial Officer, Ms. Ainhoa Mendizabal...
Biotest AG
About the publication
05 September 2024 09:00AM
Biotest AG opens 13th plasma collection center in Germany
DE0005227235
    PRESS RELEASE     Biotest AG opens 13th plasma collection center in Germany   39 plasma collection centers in Europe to ensure long-term plasma supply Dreieich, Germany, September 5, 2024. Biotest has officially opened its 13th plasma collection center in Germany in Karlsruhe. In the state-of-the-art center at Europaplatz in Kaiserstra...
Biotest AG
About the publication
28 August 2024 09:00AM
Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG
DE0005227235
    PRESS RELEASE     Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG     Dreieich, Germany, August 28, 2024. Biotest AG announced today that Dr. Jörg Schüttrumpf will in future focus on his role as Chief Scientific Innovation Officer of the entire Grifols Group. He will therefore resign from his position as Chief Sci...
Biotest AG
About the publication
06 August 2024 09:00AM
Biotest increases sales in the first half of 2024 by 35% to Euro 372 million
DE0005227235
PRESS RELEASE   Biotest increases sales in the first half of 2024 by 35% to €372 million   EBIT increased to €78.4 million FDA approval of Yimmugo® received in June 2024 FDA certification of the BNL production facility in Dreieich   Dreieich, 06 August 2024. In the first half of the 2024 financial year, the Biotest Group generated revenue ...
Biotest AG
About the publication
30 July 2024 08:00AM
Biotest increases sales in the first half of 2024 by 35% to Euro 372 million
DE0005227235
PRESS RELEASE   Biotest increases sales in the first half of 2024 by 35% to € 372 million   EBIT increased to € 78.4 million FDA approval of Yimmugo® received in June 2024 FDA certification of the BNL production facility in Dreieich Strategic distribution agreement with Kedrion is expected to generate revenues of more than $1 billion for ...
Biotest AG
About the publication
01 July 2024 09:00AM
Biotest prepares launch of its immunoglobulin Yimmugo in the USA, establishing a framework for a strategic billion-dollar distribution agreement with Kedrion
DE0005227235
PRESS RELEASE   Biotest prepares launch of its immunoglobulin Yimmugo in the USA, establishing a framework for a strategic billion-dollar distribution agreement with Kedrion   Production of U.S. launch quantities of Yimmugo® has commenced following BLA approval Biotest will start deliveries to the U.S. in Q4 2024 for the planned launch in Q1 ...
Biotest AG
About the publication
24 June 2024 02:00PM
Biotest's sustainability campaign GoFuture part of the new documentary 'Future Seeds'
DE0005227235
  PRESS RELEASE     Biotest's sustainability campaign GoFuture part of the new documentary "Future Seeds"   Documentary shows sustainable projects from around the world and the eco-art mural "Linfa" on the Biotest campus Film addresses socially relevant topic of eco-anxiety among young people Now available on Prime Video in twelve countri...
Biotest AG
About the publication
17 June 2024 09:00AM
US approval for innovative immunoglobulin Yimmugo
DE0005227235
  PRESS RELEASE     Milestone for Biotest: US approval for innovative immunoglobulin Yimmugo   FDA approval secures significant future sales and earnings growth through entry into the world's largest market Manufactured at Biotest's state-of-the-art, FDA-certified “Next Level” facility in Germany Dreieich, Germany, June 17, 2024. Biotest A...
Biotest AG
About the publication
07 May 2024 08:26PM
Annual General Meeting approves dividend distribution
DE0005227235
  PRESS RELEASE Biotest AG: Annual General Meeting approves dividend distribution Distribution of EUR 0.04 per preference share for each of the years 2023 and 2022 Broad majority in the vote in line with the management's proposals Dreieich, 07 May 2024. At the Annual General Meeting on May 7, 2024, the shareholders of Biotest AG resolved to di...
Biotest AG
About the publication
07 May 2024 09:00AM
Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024
DE0005227235
  PRESS RELEASE   Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024   Product sales increased by 17.7% to Euro 138.0 million EBIT increased to Euro 52.8 million Successful completion Fibrinogen study   Dreieich, 07 May 2024. The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 202...
Biotest AG
About the publication
19 April 2024 09:00AM
Biotest AG opens 12th plasma collection centre in Germany
DE0005227235
    PRESS RELEASE     Biotest AG opens 12th plasma collection centre in Germany   38 plasma collection centres in Europe to ensure long-term plasma supply Dreieich, 19 April 2024: Biotest has officially opened its 12th plasma collection centre in Germany in Wuppertal. In future, plasma donors will be able to donate plasma five days a week...
Biotest AG
About the publication
28 March 2024 12:38PM
Biotest AG increased sales by 32% in the financial year 2023
DE0005227235
PRESS RELEASE   Biotest AG increased sales by 32% in the financial year 2023   EBIT forecast achieved with EBIT of € 143 million Yimmugo marketing authorization application submitted to the US FDA Phase III study with fibrinogen successful Dreieich, 28 March 2024. In the financial year 2023, the Biotest Group generated revenue of € 684.6 mil...
Biotest AG
About the publication
28 March 2024 12:38PM
Biotest AG increased sales by 32% in the financial year 2023
DE0005227235
PRESS RELEASE   Biotest AG increased sales by 32% in the financial year 2023   EBIT forecast achieved with EBIT of € 143 million Yimmugo marketing authorization application submitted to the US FDA Phase III study with fibrinogen successful Dreieich, 28 March 2024. In the financial year 2023, the Biotest Group generated revenue of € 684.6 mil...
Biotest AG
About the publication
29 February 2024 07:45AM
Biotest achieves EBIT forecast for 2023
DE0005227235
    PRESS RELEASE     Biotest achieves EBIT forecast for 2023   Proposal to this year's Annual General Meeting that preference dividend for the 2023 financial year and the subsequent payment of the preference dividend for the 2022 financial year to be distributed to the preference shareholders.   Dreieich, 29 February 2024: According to p...
Biotest AG
About the publication
28 February 2024 10:00AM
Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care
DE0005227235
        PRESS RELEASE     Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care   Plasma donation in Germany secures the long-term supply of vital medicines for patients State-of-the-art plasma service centre opened in Cologne-Mülheim in January Dreieich, 28 February ...
Biotest AG
About the publication
14 February 2024 08:30AM
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate
DE0005227235
  PRESS RELEASE     Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate   Positive results confirm excellent safety profile Top-line data demonstrate that Fibrinogen concentrate treatment is as effective as standard of care, either cryoprecipitate or fresh frozen plasma, in reducing intraoperative bl...
Biotest AG
About the publication
18 January 2024 08:00AM
Biotest AG opens 11th plasma collection centre in Germany
DE0005227235
        PRESS RELEASE     Biotest AG opens 11th plasma collection centre in Germany   37 plasma collection centres in Europe to secure long term plasma supply Dreieich, 18 January 2024. Biotest has officially opened the 11th plasma collection centre in Germany in Cologne. In the ultra-modern centre on Wiener Platz in Cologne-Mülheim, p...
Biotest AG
About the publication
12 December 2023 09:00AM
Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)
DE0005227235
  PRESS RELEASE     Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)   Trimodulin is a globally unique, innovative human plasma protein preparation in advanced development Clinical development of trimodulin is conducted in two clinical trials in the therapeutic area of res...
Biotest AG
About the publication
28 November 2023 09:00AM
Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation
DE0005227235
PRESS RELEASE    Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation   Trimodulin is a globally unique, innovative human plasma protein preparation in advanced development for treatment of pneumonia Trimodulin supports and modulates the dysregulated immu...
Biotest AG
About the publication
02 November 2023 08:00AM
Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023
DE0005227235
  PRESS RELEASE Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023 Turnover grows by 38.7 % to Euro 500 million Technology transfer and licensing agreement concluded with Grifols Two new plasma centres opened Dreieich, 2 November 2023: In the first nine months of the 2023 financial year, the Biotest Group recorded r...
Biotest AG
About the publication
05 October 2023 04:55PM
Increase of the EBIT guidance
DE0005227235
    Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR)   Increase of the EBIT guidance   Dreieich, 05 October 2023. Against the background of the agreements concluded between Biotest AG, Dreieich, Germany and Grifols, S.A., Barcelona, Spain, which include a technology transfer and licensing agreement...
Biotest AG
About the publication
05 October 2023 04:42PM
Peter Janssen appointed new Chairman of the Board of Biotest AG
DE0005227235
    Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR)   Peter Janssen appointed new Chairman of the Board of Biotest AG   Dreieich, 5 October 2023. In its meeting today, the Supervisory Board of Biotest AG appointed Mr. Peter Janssen (57) as Chairman of the Management Board of Biotest AG with effect...
Biotest AG
About the publication
21 September 2023 09:00AM
Biotest receives approval for innovative immunoglobulin Yimmugo® in the UK
DE0005227235
  PRESS RELEASE     Biotest receives approval for innovative immunoglobulin Yimmugo® in the UK   New approval enables future sales growth Important therapeutic option for paediatric and adult patients with congenital and acquired immunodeficiencies as well as for immunomodulation Manufactured in highly efficient Biotest Next Level produc...
Biotest AG
About the publication
12 September 2023 09:00AM
Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin
DE0005227235
    PRESS RELEASE     Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin   Trimodulin is a globally unique, innovative human plasma protein preparation in advanced development Development in a therapeutic area of high unmet medical need Significant reduction in mortality expected i...
Biotest AG
About the publication
07 September 2023 09:00AM
US Food and Drug Administration FDA accepts marketing authorization application for immunoglobulin Yimmugo
DE0005227235
  PRESS RELEASE     US Food and Drug Administration FDA accepts marketing authorization application for immunoglobulin Yimmugo   First marketing authorization application for a Biotest product from new "Biotest Next Level" production facility for the USA Important milestone in the approval process of Yimmugo for the USA   Dreieich, 7 Sep...
Biotest AG
About the publication
05 September 2023 09:00AM
Biotest treats first shingles patient with Varitect® CP in VARIZOSTA study
DE0005227235
  PRESS RELEASE     Biotest treats first shingles patient with Varitect® CP in VARIZOSTA study   High medical need in severe cases of herpes zoster (shingles) and resulting severe chronic nerve pain. Observational study with 160 patients to generate data to optimise treatment strategy for herpes zoster Proof of efficacy and safety of Var...
Biotest AG
About the publication
04 September 2023 12:10PM
Biotest Supervisory Board extends Management Board contract of Dr Jörg Schüttrumpf by 5 years
DE0005227235
    PRESS RELEASE   Biotest Supervisory Board extends Management Board contract of Dr Jörg Schüttrumpf by 5 years   Dr Jörg Schüttrumpf to remain Chief Scientific Officer (CSO) of Biotest AG for another 5 years Appointment as Chief Scientific Innovation Officer of Grifols S.A. Dreieich, 4 September 2023. The Supervisory Board of Biotest AG...
Biotest AG
About the publication
10 August 2023 09:00AM
Biotest increases EBIT to Euro 19.8 million in the first half of 2023
DE0005227235
  PRESS RELEASE   Biotest increases EBIT to Euro 19.8 million in the first half of 2023  Turnover grows by 8.8 % to Euro 275 million Technology transfer and licensing agreement concluded with Grifols Two new plasma centres opened Dreieich, 10 August 2023: In the first half of the 2023 financial year, the Biotest Group recorded revenues of € ...
Biotest AG
About the publication
27 July 2023 08:00AM
Biotest increases EBIT to Euro 19.8 million
DE0005227235
PRESS RELEASE Biotest increases EBIT to Euro 19.8 million Sales revenue grows by 8.8 % to € 275 million Technology transfer and licensing agreement signed with Grifols Two new plasma centers opened Dreieich, 27 July 2023. In the first half of the 2023 financial year, the Biotest Group recorded sales revenues of € 275.3 million. This corresp...
Biotest AG
About the publication
27 July 2023 08:00AM
Biotest AG: Biotest increases EBIT to Euro 19.8 million
DE0005227235
PRESS RELEASE Biotest increases EBIT to Euro 19.8 million Sales revenue grows by 8.8 % to € 275 million Technology transfer and licensing agreement signed with Grifols Two new plasma centers opened Dreieich, 27 July 2023. In the first half of the 2023 financial year, the Biotest Group recorded sales revenues of € 275.3 million. This corresp...
Biotest AG
About the publication
01 June 2023 01:00PM
Biotest AG: Biotest presents gigantic artwork to visualize its sustainability initiatives
DE0005227235
  PRESS RELEASE   Biotest presents gigantic artwork to visualize its sustainability initiatives International Eco-Art artist creates large-scale mural to visualize company's sustainability efforts Special paint with sophisticated technology creates air-purifying effect With its GoFuture sustainability initiative, Biotest aims to grow in lin...
Biotest AG
About the publication
01 June 2023 01:00PM
Biotest presents gigantic artwork to visualize its sustainability initiatives
DE0005227235
  PRESS RELEASE   Biotest presents gigantic artwork to visualize its sustainability initiatives International Eco-Art artist creates large-scale mural to visualize company's sustainability efforts Special paint with sophisticated technology creates air-purifying effect With its GoFuture sustainability initiative, Biotest aims to grow in lin...
Biotest AG
About the publication
09 May 2023 04:30PM
Biotest AG: Annual General Meeting of Biotest AG elects Raimon Grifols Roura to the Supervisory Board
DE0005227235
      PRESS RELEASE   Annual General Meeting of Biotest AG elects Raimon Grifols Roura to the Supervisory Board   Broad majority on all agenda items according to the proposals of the administration Q1 report published   Dreieich, 9 May 2023. 96 shareholders and guests attended the Annual General Meeting of Biotest AG. A total of 78.15 perc...
Biotest AG
About the publication
09 May 2023 04:30PM
Annual General Meeting of Biotest AG elects Raimon Grifols Roura to the Supervisory Board
DE0005227235
      PRESS RELEASE   Annual General Meeting of Biotest AG elects Raimon Grifols Roura to the Supervisory Board   Broad majority on all agenda items according to the proposals of the administration Q1 report published   Dreieich, 9 May 2023. 96 shareholders and guests attended the Annual General Meeting of Biotest AG. A total of 78.15 perc...
Biotest AG
About the publication
04 May 2023 07:00AM
Biotest AG: Biotest’s Hyperimmunoglobulin Cytotect® CP receives five additional Marketing Authorisations in Europe
DE0005227235
PRESS RELEASE Biotest’s Hyperimmunoglobulin Cytotect® CP receives five additional Marketing Authorisations in Europe   Approval of Biotest’s CMV-hyperimmunoglobulin in now 28 markets will secure future revenue growth Biotest’s CMV-hyperimmunoglobulin is indicated for prophylaxis of clinical manifestations of cytomegalovirus (CMV) infections – a...
Biotest AG
About the publication
04 May 2023 07:00AM
Biotest’s Hyperimmunoglobulin Cytotect® CP receives five additional Marketing Authorisations in Europe
DE0005227235
PRESS RELEASE Biotest’s Hyperimmunoglobulin Cytotect® CP receives five additional Marketing Authorisations in Europe   Approval of Biotest’s CMV-hyperimmunoglobulin in now 28 markets will secure future revenue growth Biotest’s CMV-hyperimmunoglobulin is indicated for prophylaxis of clinical manifestations of cytomegalovirus (CMV) infections – a...
Biotest AG
About the publication
28 April 2023 10:04AM
Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised
DE0005227235
Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)    Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised    Dreieich, 28 April 2023. The Supervisory Board approved the signing and execution of several agreements by the Board of Management to further strengthen the c...
Biotest AG
About the publication
28 April 2023 10:04AM
Biotest AG: Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised
DE0005227235
Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)    Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised    Dreieich, 28 April 2023. The Supervisory Board approved the signing and execution of several agreements by the Board of Management to further strengthen the c...
Biotest AG
About the publication
25 April 2023 07:00AM
Biotest AG opens 12th plasma collection centre in Hungary
DE0005227235
    PRESS RELEASE   Biotest AG opens 12th plasma collection centre in Hungary   36 plasma collection stations in Europe to secure the plasma supply in the long term Dreieich, 25 April 2023. Biotest has officially opened the 12th plasma collection centre in Hungary in Budapest, after previously being granted an operating licence by the Hunga...
Biotest AG
About the publication
25 April 2023 07:00AM
Biotest AG: Biotest AG opens 12th plasma collection centre in Hungary
DE0005227235
    PRESS RELEASE   Biotest AG opens 12th plasma collection centre in Hungary   36 plasma collection stations in Europe to secure the plasma supply in the long term Dreieich, 25 April 2023. Biotest has officially opened the 12th plasma collection centre in Hungary in Budapest, after previously being granted an operating licence by the Hunga...
Biotest AG
About the publication
20 April 2023 07:00AM
Biotest AG: Biotest AG opens 10th plasma collection centre in Germany
DE0005227235
    PRESS RELEASE   Biotest AG opens 10th plasma collection centre in Germany   35 plasma collection centres in Europe to secure long term plasma supply Dreieich, 20 April 2023. Biotest has officially opened the 10th plasma collection centre in Germany in Münster in Westphalia. In future, plasma donors will be able to donate plasma six day...
Biotest AG
About the publication
20 April 2023 07:00AM
Biotest AG opens 10th plasma collection centre in Germany
DE0005227235
    PRESS RELEASE   Biotest AG opens 10th plasma collection centre in Germany   35 plasma collection centres in Europe to secure long term plasma supply Dreieich, 20 April 2023. Biotest has officially opened the 10th plasma collection centre in Germany in Münster in Westphalia. In future, plasma donors will be able to donate plasma six day...
Biotest AG
About the publication
30 March 2023 08:48AM
Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency
DE0005227235
  PRESS RELEASE   Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency   Successful interim analysis performed with 80% of evaluable patients Originally planned number of patients confirmed Completion of trial expected in 2023 AdFIrst trial will be the basis for approval of Biotest’s human fibrinogen...
Biotest AG
About the publication
More Biotest AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 1 28th April 2017 PSquared Asset Management AG SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN